Skip to main content
Edwards Lifesciences10-Q: Regulatory investigation

IRS issues Final NOPAs proposing over $2.0 billion increase to U.S. taxable income

Source: Autobound Signal API · 68 signals tracked for Edwards Lifesciences · updated

Get Edwards Lifesciences' live signals in Claude or ChatGPT, or by API

AskWhat changed at Edwards Lifesciences this week? Use Autobound signals for edwards.com.

What happened

During Q2 2026, the IRS issued two Final Notices of Proposed Adjustment proposing to increase taxable income by $233.5 million for 2018 and by $625.3 million, $530.7 million, and $683.6 million across 2018-2020 for transfer pricing on Surgical and TAVR licenses.

Source

SEC EDGARAug 4, 2026

Quarterly report (Form 10-Q)

Edwards Lifesciences 10-Q for Quarter ended Jun 30, 2026

Filing excerpt

During the second quarter of 2026, we received two draft Notices of Proposed Adjustment that were issued as final (the “Final NOPAs”) prior to the end of the second quarter. The first of the Final NOPAs relates to certain tax elections made in 2018 and proposes an increase to our U.S. taxable income in the amount of approximately $233.5 million for 2018. The second of the Final NOPAs relates to the transfer pricing of certain intercompany license transactions related to our Surgical and TAVR product groups and proposes increases to our U.S. taxable income for 2018, 2019, and 2020 in the amounts of $625.3 million, $530.7 million, and $683.6 million, respectively.

sec.gov/Archives/edgar/data/1099800/000109980026000043/ew-20260630.htmRead the full source

Other signals in this filing (3)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Regulatory investigation

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Jun 30, 2026
Fiscal year end
06/30
Filed
Aug 4, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Dollar figure
$234M (proposed increase to U.S. taxable income for 2018 under first Final NOPA)

Details

CIK
1099800
Accession number
0001099800-26-000043
Timeframe
Current quarter
Quarter
Q2
Filing year
2026
Period end date
Jun 30, 2026
Why it matters
Compliance tools urgently needed
Signal category
Risk

Topics and mentions

Regions named

  • U.S.

Extraction

Confidence
High
Relevance
80%
Sentiment
Negative
Detected
Nov 9, 2026
signal_type
sec-10q
signal_subtype
regulatoryInvestigation

Use this data

Get every 10-Q signal for Edwards Lifesciences and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Edwards Lifesciences this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/89c26fb3-c0f4-45b8-8715-a5fb99485662 returns this record as JSON. POST /v1/companies/enrich returns every signal for edwards.com.

{
  "signal_id": "89c26fb3-c0f4-45b8-8715-a5fb99485662",
  "signal_type": "sec-10q",
  "signal_subtype": "regulatoryInvestigation",
  "detected_at": "2026-11-09T06:32:58.873+00:00",
  "company": {
    "name": "Edwards Lifesciences",
    "domain": "edwards.com"
  },
  "data": {
    "detail": "During Q2 2026, the IRS issued two Final Notices of Proposed Adjustment proposing to increase taxable income by $233.5 million for 2018 and by $625.3 million, $530.7 million, and $683.6 million across 2018-2020 for transfer pricing on Surgical and TAVR licenses. The company may face potential 40% penalties in Q3 2026, creating opportunities for tax dispute, valuation, and legal advisory providers.",
    "metrics": {
      "timeframe": "current_quarter",
      "dollar_context": "proposed increase to U.S. taxable income for 2018 under first Final NOPA",
      "dollar_millions": 233.5
    },
    "quarter": "Q2",
    "summary": "IRS issues Final NOPAs proposing over $2.0 billion increase to U.S. taxable income",
    "excerpts": "During the second quarter of 2026, we received two draft Notices of Proposed Adjustment that were issued as final (the “Final NOPAs”) prior to the end of the second quarter. The first of the Final NOPAs relates to certain tax elections made in 2018 and proposes an increase to our U.S. taxable income in the amount of approximately $233.5 million for 2018. The second of the Final NOPAs relates to the transfer pricing of certain intercompany license transactions related to our Surgical and TAVR product groups and proposes increases to our U.S. taxable income for 2018, 2019, and 2020 in the amounts of $625.3 million, $530.7 million, and $683.6 million, respectively.",
    "relevance": 0.8,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1099800/000109980026000043/ew-20260630.htm",
    "filing_date": "2026-08-04",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "06/30",
    "period_end_date": "2026-06-30",
    "sales_relevance": "Compliance tools urgently needed",
    "signal_category": "risk",
    "regions_mentioned": [
      "U.S."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.